STRS Ohio’s Prelude Therapeutics PRLD Stock Holding History

STRS Ohio’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,200	Closed	-$15K	–	2229
2022 Q1	$15K	Hold	2,200	–	–	﹤0.01%	2067
2021 Q4	$27K	Hold	2,200	–	–	﹤0.01%	2082
2021 Q3	$68K	Hold	2,200	–	–	﹤0.01%	2014
2021 Q2	$62K	Hold	2,200	–	–	﹤0.01%	2071
2021 Q1	$95K	Hold	2,200	–	–	﹤0.01%	1955
2020 Q4	$157K	Buy	+2,200	New	+$109K	﹤0.01%	1801

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

STRS Ohio's PRLD Position: Q2 2022 in Review

STRS Ohio sold out of Prelude Therapeutics (PRLD) in Q2 2022, closing a stake of 2,200 shares — an estimated $15K sold.

STRS Ohio first reported a position in PRLD in Q4 2020 and held it in 6 quarters. The position peaked at $157K in Q4 2020. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

STRS Ohio reported no remaining Prelude Therapeutics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 2,200 Prelude Therapeutics shares in Q2 2022, an estimated $15K.
STRS Ohio first reported a position in Prelude Therapeutics in Q4 2020 and held it in 6 quarters.
STRS Ohio's Prelude Therapeutics position peaked at $157K in Q4 2020.
62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.